Valye reports for unlimited access

National CineMedia, Inc. is a holding company that operates a cinema advertising network primarily through its subsidiary NCM LLC. The company’s business model centers on selling advertising inventory in movie theaters across the United States, leveraging exclusive advertising service agreements (ESAs) with major theater circuits such as AMC and Cinemark. These agreements grant NCM LLC the rights to sell national, regional, and local advertising in the theaters, which represent a significant portion of the U.S. cinema market. The company’s revenue is largely dependent on theater attendance and the number of advertising impressions delivered during pre-show entertainment programming known as The Noovie® Show. NCM has been expanding its digital advertising capabilities, including acquisitions and investments in digital out-of-home advertising platforms. The company faces risks related to changes in consumer behavior, theater attendance declines, competition from alternative entertainment, and operational challenges including technology system reliability and cybersecurity. Financially, the company reported a net loss in Q2 2026 and maintains liquidity with a current ratio of 1.84 as of July 2, 2026. The company also announced a significant acquisition of Captivate Holdings to enhance its digital advertising footprint.

Rice Acquisition Corp 3 is a special purpose acquisition company (SPAC) formed in June 2025 as a Cayman Islands exempted company. Its purpose is to identify and complete a business combination with one or more target businesses using proceeds from its IPO and private placement warrants. The company completed its IPO in October 2025, raising gross proceeds of $345 million, which were placed in a trust account to be used for the initial business combination. The company has not yet selected a target or commenced operations and generates income from interest earned on trust account funds. It incurs costs related to being a public company and due diligence activities in pursuit of a business combination. The company’s capital structure includes Class A ordinary shares subject to possible redemption and Class B ordinary shares held by initial shareholders and the sponsor. Management and the board have experience in SPACs and related industries. The company’s financial statements are audited and comply with SEC reporting requirements for smaller reporting companies.

Netlist, Inc. develops and sells advanced memory and storage solutions, leveraging a portfolio of patented technologies such as distributed buffer architecture and localized power management. Its products target OEMs in server, high-performance computing, and communications markets, as well as storage and cloud customers. The company outsources manufacturing to third-party facilities in China, Taiwan, and Korea, and maintains a direct sales force and independent representatives. Netlist's business model includes both proprietary memory subsystems and reselling component products. The company holds over 200 patents and invests in emerging technologies like Compute Express Link (CXL) to address evolving data center and AI computing needs.

Intrusion Inc. operates in the cybersecurity industry, offering advanced threat intelligence and network protection solutions. Its flagship product, INTRUSION Shield, is a Zero Trust SaaS platform that analyzes network traffic and IP reputation to block malicious connections. The company also provides TraceCop, a comprehensive IP intelligence database, and Savant, a network monitoring tool used by government agencies. Intrusion’s customer base is predominantly U.S. government entities, accounting for over 90% of revenues, with a focus on federal, state, and local agencies. The company sells through direct sales and channel partners, including resellers and integrators. Intrusion faces intense competition from established cybersecurity firms but leverages proprietary data and patents to differentiate its offerings. The company has reported recurring net losses and liquidity challenges, with a need to raise additional capital to sustain operations.

Pono Capital Four, Inc. is a Cayman Islands exempted company that completed its IPO in March 2026 as a special purpose acquisition company (SPAC). The company raised $120 million through the sale of units, each comprising one Class A ordinary share and a fractional share right. PONO's business model centers on identifying and consummating a Business Combination with a target company, currently Blackstar Orbital Technologies Corporation, pursuant to a Merger Agreement executed in August 2026. The company plans to domesticate to Delaware prior to closing the Business Combination. PONO's securities are listed on Nasdaq under multiple symbols representing shares, units, and share rights. The company maintains strong liquidity and has disclosed various agreements and risk factors related to its Business Combination strategy.

Neurogene Inc. is a clinical-stage biotechnology company founded in 2018, focused on developing gene therapies for severe neurological diseases with high unmet medical need. The company has developed the EXACT platform, a proprietary microRNA-based transgene regulation technology designed to precisely control gene expression and widen the therapeutic window for dosage-sensitive neurological diseases. Neurogene's lead clinical program is NGN-401, a gene therapy for Rett syndrome, which is in Phase 3 clinical development. Rett syndrome is a severe neurodevelopmental disorder caused by mutations in the MECP2 gene, requiring precise gene expression control to avoid toxicity. NGN-401 is administered via intracerebroventricular infusion to target key brain regions. The company has completed dosing in Phase 1/2 trials and is conducting the Embolden Phase 3 trial. Neurogene operates an in-house cGMP manufacturing facility and collaborates with the University of Edinburgh for research and pipeline development. The company has incurred significant losses since inception and funds operations primarily through equity financing.

Evolv Technologies Holdings, Inc. develops and markets AI-powered security screening solutions designed to enhance safety while maintaining efficient visitor flow and a positive experience. The company's platform integrates proprietary hardware (Evolv Express® for people screening and Evolv eXpedite™ for bag screening) with AI software, cloud services, and ongoing support under a Security-as-a-Service subscription model. Evolv's solutions are deployed across a wide range of venues including schools, hospitals, sports arenas, entertainment venues, industrial workplaces, and houses of worship. The company leverages a large proprietary data set to continuously improve detection algorithms and provides customers with operational analytics through its Evolv Insights® platform. Its growth strategy focuses on geographic and vertical market expansion, reseller network development, customer referrals, and product line extensions. Evolv faces competition from legacy metal detectors and other screening technologies but differentiates through AI capabilities, integrated hardware-software design, and data-driven insights.

Brookfield Oaktree Holdings, LLC is a limited liability holding company that holds limited partner interests in private investment funds managed by Oaktree Capital Management. The company’s primary business involves capital commitments to Oaktree Opportunities Fund XI and Fund XII, with funding provided by its sole Class A unitholder. Distributions from these investments are intended to benefit the Class A unitholder, and preferred unitholders rely on distributions from Oaktree Capital I for payments. The company operates under a complex legal and tax structure, including provisions that limit remedies for preferred unitholders and modify fiduciary duties of officers and directors. The company is not considered an investment company under the Investment Company Act, which influences its regulatory environment and operational flexibility.

Strategic Storage Trust VI, Inc. is a Maryland corporation focused on investing in self storage facilities. It commenced operations in March 2021 and operates primarily through its Operating Partnership, which holds the self storage properties. The company has no employees and relies on its Advisor and Property Manager, subsidiaries of its Sponsor SmartStop REIT Advisors, LLC, for management and property services. It has issued multiple classes of common stock and preferred stock series through private and public offerings, including a distribution reinvestment plan. As of late 2025, it owned 24 operating self storage properties across the U.S. and Canada, plus development properties and interests in unconsolidated ventures. The company’s business model centers on acquiring, managing, and generating rental income from self storage facilities.

Maze Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapeutics, including a kidney disease drug candidate MZE829. The company is headquartered in South San Francisco, California, and is publicly traded on Nasdaq under the ticker MAZE. Maze Therapeutics operates with strong liquidity, supported by cash, short-term investments, and current assets significantly exceeding current liabilities. The company has licensing and consortium agreements with academic and industry partners, which support its research and development efforts. Recent clinical trial results have been positive, and the company has engaged in capital raising activities to support ongoing operations.

Mobia Medical, Inc. is a company with publicly available quarterly financial data as of June 30, 2026. The company reported revenue and net losses for the quarter, alongside a strong liquidity position. Specific details about its sector, industry, and business model are not disclosed in the available data.

Siebert Financial Corp. is a diversified financial services company with operations in brokerage, investment advisory, insurance, technology development, and media, sports, and entertainment. The company operates through several subsidiaries including Muriel Siebert & Co., LLC (retail brokerage), Siebert AdvisorNXT (investment advisory), Park Wilshire (insurance), Siebert Technologies (technology), RISE Financial Services (broker-dealer), Gebbia Media (media and entertainment), and Siebert Crypto (digital assets, not yet operational). The firm offers a broad range of financial products and services such as self-directed trading, market making, equity compensation plans, wealth management, investment banking, and insurance products. It also invests in technology platforms to enhance client experience and operational efficiency. The media segment includes talent management, sports negotiation, and content production, with recent acquisitions expanding its music and sports presence. The company is listed on Nasdaq under ticker SIEB and has 166 employees with 13 branch offices across the U.S. [S1].

Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to developing bifunctional therapies that precisely target solid tumors by delivering tumor-modulating payloads directly to the tumor microenvironment. Its lead product candidate, ficerafusp alfa, is a bifunctional antibody combining an EGFR-directed monoclonal antibody with a TGF-beta ligand trap. This dual-targeting approach aims to block cancer cell survival and proliferation pathways while modulating the immunosuppressive tumor microenvironment to enhance immune cell penetration and anti-tumor activity. The company is primarily focused on head and neck squamous cell carcinoma (HNSCC), especially first-line recurrent/metastatic HPV-negative patients, where EGFR and TGF-beta pathways are overexpressed and linked to poor prognosis and resistance to existing therapies. Bicara is conducting a global Phase 2/3 pivotal trial evaluating ficerafusp alfa in combination with pembrolizumab, with prior Phase 1/1b trials establishing safety and dose selection. The company has not yet generated revenue and funds operations through equity offerings. It relies on third-party manufacturers for clinical and potential commercial supply. Bicara faces typical risks of clinical-stage biopharmaceutical companies, including regulatory, clinical, financial, and competitive challenges.

Tron Inc. is a publicly traded company that has transformed its business to focus on blockchain-integrated treasury strategies centered on the TRON blockchain and its native TRX token. The company holds the largest public TRX token holdings and stakes these tokens through the JustLend decentralized finance protocol to earn yield. Alongside this, Tron Inc. operates a toy and souvenir business through its wholly owned subsidiary, SRM Entertainment Limited, which designs and manufactures licensed merchandise for major theme parks and entertainment venues globally. The company’s products are based on popular entertainment franchises and are distributed at venues including Walt Disney Parks and Resorts, Universal Studios, SeaWorld, and Six Flags. Tron Inc. was incorporated in 2022 and acquired SRM Entertainment Limited in 2023. The company’s treasury wallet is self-managed and secured in Hong Kong with regulated custodial oversight. Financially, the company reported strong liquidity and net income in the latest quarter, though its toy and souvenir business has not generated positive cash flow from operations recently. Tron Inc. continues to pursue capital raising to support its TRX token accumulation strategy and business operations [S1][S2].

Jaws Mustang Acquisition Corp is a Cayman Islands-incorporated special purpose acquisition company (SPAC) that has issued Class A and Class B ordinary shares along with redeemable warrants. The company’s securities are traded on the OTCID Basic Market. As a SPAC, it primarily holds cash and cash equivalents and has not disclosed operational revenues or detailed business activities in its filings. The company’s financial position as of June 30, 2026, shows limited liquidity relative to current liabilities, and it reported net income for the period. The company’s filings do not provide information on its sector, industry, or specific business model.

Interface, Inc. is a global manufacturer and marketer of flooring solutions, including carpet tile, luxury vinyl tile (LVT), and rubber flooring. The company has evolved from a modular carpet focus to an integrated flooring solutions provider with a broad product portfolio marketed under established brands such as Interface, FLOR, noraplan, and norament. Interface operates two reportable segments: Americas (AMS) and Europe, Africa, Asia and Australia (EAAA). The company serves diverse market segments including corporate office, education, healthcare, government, hospitality, and residential living. Manufacturing is global, with facilities in the US, Europe, Asia, and Australia. Interface emphasizes sustainability leadership, offering carbon negative products and setting science-based carbon reduction targets. Sales are conducted through direct and indirect channels, supported by a global marketing and design infrastructure. The One Interface strategy aims to unify operations and accelerate growth across the integrated product portfolio.

BridgeBio Oncology Therapeutics, Inc. (BBOT) is a clinical-stage biotechnology company focused on developing precision oncology therapies targeting the two most frequently mutated oncogenes in human cancers: RAS and PI3Kα. The company’s pipeline consists of three orally bioavailable small molecule inhibitors—BBO-8520, BBO-11818, and BBO-10203—designed to achieve high levels of target inhibition with favorable tolerability. BBO-8520 is a dual KRAS G12C ON/OFF inhibitor in Phase 1 trials for non-small cell lung cancer (NSCLC). BBO-11818 is a pan-KRAS ON/OFF inhibitor in Phase 1 trials for KRAS mutant solid tumors and has received FDA Fast Track designation for KRAS-mutant pancreatic cancer. BBO-10203 targets the RAS-binding domain of PI3Kα to selectively inhibit oncogenic signaling while avoiding hyperglycemia, currently in Phase 1 trials for breast and colorectal cancers. The company is also developing combination therapies from its pipeline to inhibit multiple oncogenic pathways simultaneously. BBOT has not yet generated revenue or received regulatory approval for any product. It relies on third parties for clinical trials and manufacturing. The company has reported significant net losses and maintains strong liquidity as of mid-2026.

Neutron Holdings, Inc. is a publicly traded company on Nasdaq under the ticker LIME. The company completed its initial public offering in July 2026, issuing nearly 7 million shares. It operates with a strong liquidity profile, holding $278 million in cash and equivalents and maintaining a current ratio of 1.6 as of the end of Q2 2026. The company reported $304 million in revenue and $295 million in net income for Q2 2026, with basic EPS of $26.70 and diluted EPS of $4.73. It has a $200 million senior secured revolving credit facility established in July 2026, which is currently undrawn. The company used IPO proceeds to repay a prior $115 million term loan facility in full, releasing associated liens and obligations. Public disclosures do not provide detailed information on the company's sector, industry, or specific business operations.

Immunome Inc. is a biotechnology company focused on developing first-in-class and best-in-class targeted oncology therapies. Its core expertise lies in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates (ADCs) and other oncology therapeutics. The company’s pipeline includes three clinical-stage assets: varegacestat, an oral gamma secretase inhibitor targeting desmoid tumors; IM-1021, a ROR1-targeted ADC in Phase 1 trials for hematologic and solid tumors; and IM-3050, a fibroblast activation protein (FAP)-targeted radioligand therapy with planned Phase 1 initiation. Additionally, Immunome has three preclinical ADC candidates with anticipated IND submissions and a broader discovery pipeline. The company is advancing regulatory and commercial preparations for varegacestat, including NDA submission and staged commercial capability build-out. Immunome operates as a single segment focused on targeted oncology therapies in the U.S. and has reported significant operating losses consistent with its clinical-stage status.

Energy Vault Holdings, Inc. operates as a technology-agnostic energy infrastructure platform delivering a diversified portfolio of energy storage solutions globally. Its offerings include proprietary battery energy storage systems (B-VAULT), gravity-based storage (G-VAULT), and hydrogen hybrid systems (H-VAULT), complemented by software solutions for asset management and optimization. The company has shifted from primarily licensing and build-transfer models to an integrated approach involving development, ownership, and operation of energy storage assets through its Asset Vault platform, backed by a $300 million preferred equity commitment. Energy Vault manages projects across the full lifecycle and serves utilities, independent power producers, and large energy users. It is also exploring modular data center infrastructure to support AI and high-density compute workloads. The company operates projects in the U.S., Australia, and Europe, with recent commercial operations including the Cross Trails battery system in Texas and the Calistoga hybrid microgrid in California. Energy Vault's strategy leverages its technology diversity, integration capabilities, and software to address evolving market needs and regulatory environments [S1][S2].

Aquestive Therapeutics, Inc. is a pharmaceutical company specializing in the development and commercialization of proprietary oral film drug delivery technologies under its PharmFilm platform. The company manufactures licensed products such as Suboxone and Ondif, and develops pipeline candidates including Libervant for acute repetitive seizures and Anaphylm for emergency treatment of allergic reactions. Manufacturing is conducted at two cGMP-compliant facilities in Indiana, which have passed regulatory inspections and have capacity for current and future products. Aquestive holds a broad patent portfolio protecting its technology and product candidates. The company operates within a competitive pharmaceutical landscape with regulatory oversight from the FDA and other agencies. Recent regulatory challenges include a court ruling affecting Libervant’s marketing status and a complete response letter for Anaphylm’s NDA, with plans for resubmission. Financially, the company reported a net loss in Q2 2026 but maintains strong liquidity with a current ratio above 7.0 [S1][S2][N1][N6].

NextNav Inc. delivers complementary positioning, navigation and timing (PNT) solutions designed to overcome vulnerabilities of satellite-based GPS systems. Its technology uses a ground-based transmitter network operating on low-band spectrum, providing stronger, more resilient signals capable of penetrating buildings and urban environments. The company offers three-dimensional location services, including vertical positioning via its Pinnacle technology, primarily used in public safety and E911 applications. Pinnacle operates in partnership with AT&T and covers over 90% of commercial buildings over three stories in the U.S. NextNav also operates TerraPoiNT, a prior-generation terrestrial PNT system. The company is evolving its platform to NextGen, which integrates 5G New Radio (5G NR) positioning reference signals to deliver both PNT and broadband data services on the same spectrum. NextGen aims to provide a resilient terrestrial PNT network complementing GPS, leveraging cellular infrastructure and partnerships with wireless operators. Revenue is generated from contracts with wireless carriers, application developers, government entities, equipment sales, and licensing. The company faces competition from free location services by large technology firms and depends on third-party adoption of its technology integrated into devices and applications. NextNav holds FCC licenses covering 12 MHz of low-band spectrum and is pursuing regulatory approvals to optimize spectrum use for 5G NR operations. The business model relies on partnerships, regulatory success, and market adoption to scale operations and achieve profitability.

Achieve Life Sciences, Inc. operates as a late-stage clinical specialty pharmaceutical company developing cytisinicline, a drug candidate intended to aid smoking cessation. The company submitted a New Drug Application to the FDA in June 2025 and has been actively engaged in clinical development, manufacturing scale-up, and commercial launch preparations. The FDA issued a Complete Response Letter in June 2026 citing manufacturing compliance issues. The company has raised capital through public offerings and private placements to fund its operations and development activities. As of mid-2026, Achieve Life Sciences has not generated product sales revenue and continues to incur operating losses. The Board of Directors comprises individuals with extensive experience in biopharma, investment, and clinical development.

Absci Corp operates as a clinical-stage biopharmaceutical company leveraging its Integrated Drug Creation platform to develop internally originated drug candidates and to collaborate with partners on drug creation programs. The company is in early stages of clinical and preclinical development, with no commercial products approved or generating revenue. Its revenue to date derives primarily from drug creation activities under partnered programs, which are milestone and fee-based. Absci has incurred substantial losses since inception and maintains a strong liquidity position as of mid-2026. The company plans to continue advancing its internally developed programs and expanding its platform capabilities, while seeking additional capital to support operations and development activities.

Anterix Inc. operates as the largest holder of licensed 900 MHz spectrum in the United States, providing critical infrastructure connectivity solutions primarily to utility and critical infrastructure enterprises. The company’s spectrum assets cover the contiguous U.S., Hawaii, Alaska, and Puerto Rico. Anterix’s business model has evolved from predominantly long-term spectrum leasing to a broader operating model that includes securing and expanding spectrum holdings, clearing and retuning spectrum to broadband licenses, monetizing spectrum through sales and leases, and developing products and services to generate recurring revenue streams. Key product offerings include TowerX, a tower site access service, and CatalyX, a turnkey connectivity management solution. The company’s spectrum aligns with international 3GPP Band 8 standards, supporting 4G and 5G technologies. Anterix serves customers focused on grid modernization, operational resilience, and digital transformation. The company reported $1.958 million in revenue and $0.24 million in net income for the quarter ended June 30, 2026, with strong liquidity ratios indicating financial stability.

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing integrin-based therapeutics targeting fibrotic diseases and cancer. The company’s lead product candidate, PLN-101095, is in Phase 1 clinical trials for solid tumors. Pliant has no approved products or revenue from sales and has historically financed operations through equity, debt, and collaborations. The company discontinued development of bexotegrast in IPF following safety concerns and trial discontinuation. Pliant relies on third-party suppliers and contract manufacturers without long-term supply agreements, which introduces supply chain risks. The company has limited internal development and no commercialization capabilities, relying on partnerships for these functions. As of June 30, 2026, Pliant held approximately $159.6 million in cash and short-term investments, with strong liquidity ratios. The company continues to incur significant losses as it advances clinical development and prepares for potential commercialization.

Gain Therapeutics, Inc. is a biotechnology company developing novel small molecule therapeutics targeting diseases caused by protein misfolding. The company’s lead clinical candidate, GT-02287 (rexaceract), is being developed for Parkinson’s disease with and without GBA1 mutations. Preclinical studies demonstrate restoration of glucocerebrosidase function and neuroprotective effects. Clinical development includes completed Phase 1a and ongoing Phase 1b studies, with a Phase 2 study authorized by the FDA as of June 2026. The company uses its proprietary Magellan™ platform to identify allosteric binding sites and develop therapeutics across multiple disease areas. Financially, Gain Therapeutics reported a net loss in Q2 2026, with a solid liquidity position supported by cash and equivalents of approximately $13.1 million and a current ratio of 4.36. The company operates as a single segment focused on research and development in pharmaceuticals.

Taysha Gene Therapies, Inc. operates in the biotechnology sector, specializing in the development of gene therapies. The company is engaged in clinical development programs, including TSHA-102 targeting Rett Syndrome, which has received regulatory attention. As of mid-2026, Taysha maintains a strong liquidity position with over $455 million in cash and equivalents and minimal current liabilities. The company has no reported revenue and continues to operate at a net loss, reflecting its development-stage status. Recent capital raising activities include a $200 million offering of shares and warrants. The company is subject to typical industry risks such as regulatory approval challenges, clinical trial outcomes, and market volatility. It also faces operational risks related to cybersecurity and key personnel retention.

Hoyne Bancorp, Inc. was incorporated in June 2025 and completed its conversion to a stock form of ownership in December 2025, becoming a savings and loan holding company regulated by the Federal Reserve Board. It owns all shares of Hoyne Savings Bank, which operates six full-service banking offices in Cook County, Illinois, serving the Chicago metropolitan area. The bank has a 138-year history and focuses on residential and commercial real estate lending, with a diversified loan portfolio. The company completed a stock offering raising approximately $79.4 million and its shares trade on Nasdaq under the ticker HYNE. The bank faces significant competition from larger financial institutions and non-depository entities. It has optimized its branch network recently to adapt to changing market conditions and banking habits.

Dermata Therapeutics, Inc. is a skincare company dedicated to developing and commercializing products addressing common and underserved skin conditions. Initially focused on prescription products, Dermata achieved positive Phase 3 clinical trial results for its lead acne drug candidate XYNGARI (DMT310). In 2025, the company shifted its strategy to focus on direct-to-consumer and B2B cosmetic and OTC skincare products, leveraging its proprietary Bioneedle technology derived from the freshwater sponge Spongilla lacustris. Dermata plans to launch its first cosmetic and OTC acne products in mid-2026, selling through its website and medical professionals. The company aims to expand its product portfolio to treat various skin diseases and build a network of certified skincare professionals. Dermata also faces ongoing litigation related to its Spongilla-based products and Nasdaq listing risks.

Cambridge Acquisition Corp. operates as a Special Purpose Acquisition Company (SPAC) incorporated in the Cayman Islands. Its primary business model is to raise capital through an IPO and private placement to fund a future Business Combination with a target company. The company targets sectors involving harm-reduction innovation, wellness-oriented products, and technology-enabled platforms, with a focus on the US and European markets but with flexibility to pursue other geographies. The management team brings experience in stigmatized and underserved markets and has a history of backing category leaders in related sectors. The company has not yet identified a specific acquisition target and currently holds funds in a trust account. It plans to use these funds, along with potential additional financing, to complete its initial Business Combination. The company’s shares and warrants trade on Nasdaq under the tickers CAQ, CAQUU, and CAQUW respectively. The company’s financial position as of June 30, 2026, shows strong liquidity with a current ratio of 7.47. The company faces typical SPAC risks including the uncertainty of completing a Business Combination and reliance on a single business post-combination.

SharonAI Holdings Inc. is an Australian-based neocloud operator focused on providing specialized AI and high-performance computing infrastructure. The company offers GPU-as-a-Service, a proprietary AI Studio platform, and cloud storage solutions designed to accelerate complex AI workloads such as large language model training, inference, scientific simulations, and visual computing. SharonAI leverages partnerships with NVIDIA, NEXTDC, Cisco, and others to deliver integrated AI infrastructure solutions without customers needing to manage physical hardware. The company deploys its infrastructure in partner-operated data centers under long-term contracts, enabling rapid and capital-efficient scaling. SharonAI has developed a supercluster of over 1,000 GPUs for large-scale AI workloads and has expanded its GPU fleet with recent acquisitions. It transitioned to a pure-play neocloud operator model in late 2025 and completed significant capital raises, including a $125 million public offering in early 2026. The company targets enterprise, government, hyperscaler, and research customers requiring deterministic performance for AI and HPC applications [S1][S2].

GrowGeneration Corp. was founded in 2014 and has expanded from a small chain of specialty hydroponic and organic garden centers to a multifaceted company with two reportable segments: Cultivation and Gardening, and Storage Solutions. The Cultivation and Gardening segment offers a wide range of products for indoor and outdoor hydroponic and organic gardening, including proprietary brands, distributed through retail locations, commercial sales, wholesale, and online channels. The Storage Solutions segment, operating under the Mobile Media brand, provides customized storage systems and related services to diverse industries including agriculture, retail, and controlled environment agriculture. The company’s growth strategy includes expanding proprietary brands, commercial and wholesale channels, and selective acquisitions. Seasonal sales patterns affect both segments, with higher sales typically in the second and third quarters. The company has implemented a strategic restructuring plan to improve profitability and operational efficiency.

TOFUTTI BRANDS INC specializes in plant-based, dairy free frozen desserts and cheese products that are vegan, cholesterol free, and use soy and vegetable proteins. Its product portfolio includes cream cheese alternatives, sour cream, ricotta, American vegan cheese slices, and frozen dessert novelties like TOFUTTI CUTIES®. The company markets primarily to consumers with dietary restrictions or preferences related to health, lifestyle, or religion, emphasizing product innovation and brand awareness. Distribution spans the United States and approximately a dozen international markets, utilizing co-packers and third-party warehouses. The company maintains Kosher and Halal certifications for many products and complies with FDA labeling and quality regulations. Competition is intense from both dairy and plant-based producers, including private label brands. Financially, the company reported a net loss in Q2 2026 and maintains liquidity with a current ratio above 3.0. Product development continues at a moderate level despite scaled-back laboratory operations.

SUMA Acquisition Corp is a smaller reporting company under SEC rules, with limited publicly available information about its business operations or industry classification. The latest SEC 10-Q filing dated August 11, 2026, provides basic financial snapshot data including liquidity and net income but does not disclose revenue or detailed operational metrics. The company refers to previously disclosed risk factors from its IPO Registration Statement and earlier quarterly filings, with no material updates as of the latest report.

Syra Health Corp is a healthcare services company focused on providing healthcare workforce solutions and mental health access services. The company operates primarily through government contracts and partnerships, including recent awards in Indiana and Washington D.C. Syra Health's leadership team has significant experience in healthcare technology, population health, and managed care markets. The company maintains strong liquidity with a current ratio above 3 and reported positive net income and earnings per share in the latest quarter ending June 30, 2026.